Top

Published in:

12-04-2022 | Hypertension

Association Between Serum Selenium Concentration and OPG/RANKL/RANK Axis in Patients with Arterial Hypertension

Authors: Karolina Czerwińska, Małgorzata Poręba, Adam Prokopowicz, Lidia Januszewska, Aleksandra Jaremków, Iwona Markiewicz-Górka, Helena Martynowicz, Grzegorz Mazur, Rafał Poręba, Krystyna Pawlas, Paweł Gać

Published in: Cardiovascular Toxicology | Issue 7/2022

Abstract

The aim of the study was to determine the relationship between the serum selenium concentration (Se–S) and the blood concentrations of osteoprotegerin (OPG), receptor activator of nuclear factor kappa-Β ligand (RANKL) and the OPG/RANKL ratio in patients with arterial hypertension. The study group comprised 138 patients with arterial hypertension (age: 56.04 ± 11.59 years). Se–S was determined in all the subjects. Based on the Se–S, the following subgroups were distinguished: a subgroup of patients with a lower Se–S ("low-Se", Se–S < median) and a subgroup of patients with a higher Se–S ("high-Se", Se–S ≥ median). Moreover, the blood concentrations of the parameters of bone metabolism and extraskeletal calcification were assessed: OPG and RANKL. The OPG/RANKL ratio was calculated. In the "low-Se" subgroup, the RANKL concentration was statistically significantly lower, and the OPG/RANKL ratio was statistically significantly higher than in the patients in the "high-Se" subgroup. The correlation analysis showed the negative linear relationships between Se–S and OPG (r = − 0.25, p < 0.05) and between Se–S and OPG/RANKL (r = − 0.47, p < 0.05). Moreover, Se–S positively correlated with RANKL (r = 0.33, p < 0.05). In regression analysis, higher body mass index (BMI), smoking and lower Se–S were independently associated with a higher OPG/RANKL ratio, while lower BMI, use of diuretics, β-blockers and ACE inhibitors and lower OPG/RANKL ratio with effective blood pressure control. In summary, in the group of patients with arterial hypertension, lower Se–S is associated with an unfavourable prognostic panel of parameters of bone metabolism and extraskeletal calcification. Lower Se–S is an independent risk factor for a higher OPG/RANKL ratio, which is an independent prediction factor of ineffective blood pressure control in patients with hypertension.

NCD Risk Factor Collaboration (NCD-RisC). (2021). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: A pooled analysis of 1201 population-representative studies with 104 million participants. Lancet, 398(10304), 957–980. https://doi.org/10.1016/S0140-6736(21)01330-1CrossRef

Nguyen, T. N., & Chow, C. K. (2021). Global and national high blood pressure burden and control. Lancet, 398(10304), 932–933. https://doi.org/10.1016/S0140-6736(21)01688-3CrossRefPubMed

GBD 2019 Risk Factors Collaborators. (2020). Global burden of 87 risk factors in 204 countries and territories, 1990–2019: A systematic analysis for the Global Burden of Disease Study 2019. Lancet, 396(10258), 1223–1249. https://doi.org/10.1016/S0140-6736(20)30752-2CrossRef

Nakanishi, R., Baskaran, L., Gransar, H., Budoff, M. J., Achenbach, S., Al-Mallah, M., Cademartiri, F., Callister, T. Q., Chang, H. J., Chinnaiyan, K., Chow, B., DeLago, A., Hadamitzky, M., Hausleiter, J., Cury, R., Feuchtner, G., Kim, Y. J., Leipsic, J., Kaufmann, P. A., Maffei, E., et al. (2017). Relationship of hypertension to coronary atherosclerosis and cardiac events in patients with coronary computed tomographic angiography. Hypertension, 70(2), 293–299. https://doi.org/10.1161/HYPERTENSIONAHA.117.09402CrossRefPubMed

Simonet, W. S., Lacey, D. L., Dunstan, C. R., Kelley, M., Chang, M. S., Lüthy, R., Nguyen, H. Q., Wooden, S., Bennett, L., Boone, T., Shimamoto, G., DeRose, M., Elliott, R., Colombero, A., Tan, H. L., Trail, G., Sullivan, J., Davy, E., Bucay, N., Renshaw-Gegg, L., et al. (1997). Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell, 89(2), 309–319. https://doi.org/10.1016/s0092-8674(00)80209-3CrossRefPubMed

Boyce, B. F., & Xing, L. (2007). Biology of RANK, RANKL, and osteoprotegerin. Arthritis Research and Therapy, 9 Suppl 1(Suppl 1), S1. https://doi.org/10.1186/ar2165CrossRefPubMed

Rochette, L., Meloux, A., Rigal, E., Zeller, M., Cottin, Y., & Vergely, C. (2019). The role of osteoprotegerin and its ligands in vascular function. International Journal of Molecular Sciences, 20(3), 705. https://doi.org/10.3390/ijms20030705CrossRefPubMedCentral

Pérez de Ciriza, C., Lawrie, A., & Varo, N. (2015). Osteoprotegerin in cardiometabolic disorders. International Journal of Endocrinology, 2015, 564934. https://doi.org/10.1155/2015/564934CrossRefPubMedPubMedCentral

Venuraju, S. M., Yerramasu, A., Corder, R., & Lahiri, A. (2010). Osteoprotegerin as a predictor of coronary artery disease and cardiovascular mortality and morbidity. Journal of the American College of Cardiology, 55(19), 2049–2061. https://doi.org/10.1016/j.jacc.2010.03.013CrossRefPubMed

10.

Wu, J., Li, X., Gao, F., Gao, S., Lyu, J., & Qiang, H. (2020). Osteoprotegerin SNP associations with coronary artery disease and ischemic stroke risk: a meta-analysis. Bioscience Reports, 40(10), BSR20202156. https://doi.org/10.1042/BSR20202156CrossRefPubMedPubMedCentral

11.

Tschiderer, L., Willeit, J., Schett, G., Kiechl, S., & Willeit, P. (2017). Osteoprotegerin concentration and risk of cardiovascular outcomes in nine general population studies: Literature-based meta-analysis involving 26,442 participants. PLoS ONE, 12(8), e0183910. https://doi.org/10.1371/journal.pone.0183910CrossRefPubMedPubMedCentral

12.

Hariharan, S., & Dharmaraj, S. (2020). Selenium and selenoproteins: It’s role in regulation of inflammation. Inflammopharmacology, 28(3), 667–695. https://doi.org/10.1007/s10787-020-00690-xCrossRefPubMedPubMedCentral

13.

Senoner, T., & Dichtl, W. (2019). Oxidative stress in cardiovascular diseases: Still a therapeutic target? Nutrients, 11(9), 2090. https://doi.org/10.3390/nu11092090CrossRefPubMedCentral

14.

Liu, H., Xu, H., & Huang, K. (2017). Selenium in the prevention of atherosclerosis and its underlying mechanisms. Metallomics, 9(1), 21–37. https://doi.org/10.1039/c6mt00195eCrossRefPubMed

15.

Parati, G., Stergiou, G., O’Brien, E., Asmar, R., Beilin, L., Bilo, G., Clement, D., de la Sierra, A., de Leeuw, P., Dolan, E., Fagard, R., Graves, J., Head, G. A., Imai, Y., Kario, K., Lurbe, E., Mallion, J. M., Mancia, G., Mengden, T., Myers, M., et al. (2014). European Society of Hypertension practice guidelines for ambulatory blood pressure monitoring. Journal of Hypertension, 32(7), 1359–1366. https://doi.org/10.1097/HJH.0000000000000221CrossRefPubMed

16.

Stoffaneller, R., & Morse, N. L. (2015). A review of dietary selenium intake and selenium status in Europe and the Middle East. Nutrients, 7(3), 1494–1537. https://doi.org/10.3390/nu7031494CrossRefPubMedPubMedCentral

17.

Hoeg, A., Gogakos, A., Murphy, E., Mueller, S., Köhrle, J., Reid, D. M., Glüer, C. C., Felsenberg, D., Roux, C., Eastell, R., Schomburg, L., & Williams, G. R. (2012). Bone turnover and bone mineral density are independently related to selenium status in healthy euthyroid postmenopausal women. The Journal of Clinical Endocrinology and Metabolism, 97(11), 4061–4070. https://doi.org/10.1210/jc.2012-2121CrossRefPubMed

18.

Akbaraly, T. N., Arnaud, J., Rayman, M. P., Hininger-Favier, I., Roussel, A. M., Berr, C., & Fontbonne, A. (2010). Plasma selenium and risk of dysglycemia in an elderly French population: Results from the prospective Epidemiology of Vascular Ageing Study. Nutrition & Metabolism, 7, 21. https://doi.org/10.1186/1743-7075-7-21CrossRef

19.

Galan, P., Viteri, F. E., Bertrais, S., Czernichow, S., Faure, H., Arnaud, J., Ruffieux, D., Chenal, S., Arnault, N., Favier, A., Roussel, A. M., & Hercberg, S. (2005). Serum concentrations of beta-carotene, vitamins C and E, zinc and selenium are influenced by sex, age, diet, smoking status, alcohol consumption and corpulence in a general French adult population. European journal of clinical nutrition, 59(10), 1181–1190. https://doi.org/10.1038/sj.ejcn.1602230CrossRefPubMed

20.

González, S., Huerta, J. M., Fernández, S., Patterson, E. M., & Lasheras, C. (2006). Food intake and serum selenium concentration in elderly people. Annals of nutrition & metabolism, 50(2), 126–131. https://doi.org/10.1159/000090633CrossRef

21.

Spina, A., Guallar, E., Rayman, M. P., Tigbe, W., Kandala, N. B., & Stranges, S. (2013). Anthropometric indices and selenium status in British adults: The U.K. National Diet and Nutrition Survey. Free Radical Biology & Medicine, 65, 1315–1321. https://doi.org/10.1016/j.freeradbiomed.2013.09.025CrossRef

22.

Rayman, M. P., Blundell-Pound, G., Pastor-Barriuso, R., Guallar, E., Steinbrenner, H., & Stranges, S. (2012). A randomized trial of selenium supplementation and risk of type-2 diabetes, as assessed by plasma adiponectin. PLoS ONE, 7(9), e45269. https://doi.org/10.1371/journal.pone.0045269CrossRefPubMedPubMedCentral

23.

Stranges, S., Laclaustra, M., Ji, C., Cappuccio, F. P., Navas-Acien, A., Ordovas, J. M., Rayman, M., & Guallar, E. (2010). Higher selenium status is associated with adverse blood lipid profile in British adults. The Journal of Nutrition, 140(1), 81–87. https://doi.org/10.3945/jn.109.111252CrossRefPubMedPubMedCentral

24.

Duffield, A. J., Thomson, C. D., Hill, K. E., & Williams, S. (1999). An estimation of selenium requirements for New Zealanders. The American Journal of Clinical Nutrition, 70(5), 896–903. https://doi.org/10.1093/ajcn/70.5.896CrossRefPubMed

25.

Alfthan, G., Aro, A., Arvilommi, H., & Huttunen, J. K. (1991). Selenium metabolism and platelet glutathione peroxidase activity in healthy Finnish men: Effects of selenium yeast, selenite, and selenate. The American Journal of Clinical Nutrition, 53(1), 120–125. https://doi.org/10.1093/ajcn/53.1.120CrossRefPubMed

26.

Vinceti, M., Chawla, R., Filippini, T., Dutt, C., Cilloni, S., Loomba, R., Bargellini, A., Orsini, N., Dhillon, K. S., & Whelton, P. (2019). Blood pressure levels and hypertension prevalence in a high selenium environment: Results from a cross-sectional study. Nutrition, Metabolism, and Cardiovascular Diseases: NMCD, 29(4), 398–408. https://doi.org/10.1016/j.numecd.2019.01.004CrossRefPubMed

27.

Grotto, D., Carneiro, M., de Castro, M. M., Garcia, S. C., & Barbosa Junior, F. (2018). Long-term excessive selenium supplementation induces hypertension in rats. Biological Trace Element Research, 182(1), 70–77. https://doi.org/10.1007/s12011-017-1076-1CrossRefPubMed

28.

Hu, X. F., Eccles, K. M., & Chan, H. M. (2017). High selenium exposure lowers the odds ratios for hypertension, stroke, and myocardial infarction associated with mercury exposure among Inuit in Canada. Environment International, 102, 200–206. https://doi.org/10.1016/j.envint.2017.03.002CrossRefPubMed

29.

Gharipour, M., Sadeghi, M., Behmanesh, M., Salehi, M., Nezafati, P., & Gharpour, A. (2017). Selenium homeostasis and clustering of cardiovascular risk factors: A systematic review. Acta Biomedica, 88(3), 263–270. https://doi.org/10.23750/abm.v88i3.5701CrossRefPubMedPubMedCentral

30.

Huang, Q. X., Li, J. B., Huang, N., Huang, X. W., Li, Y. L., & Huang, F. X. (2020). Elevated osteoprotegerin concentration predicts increased risk of cardiovascular mortality in patients with chronic kidney disease: A systematic review and meta-analysis. Kidney & Blood Pressure Research, 45(4), 565–575. https://doi.org/10.1159/000508978CrossRef

31.

Collin-Osdoby, P. (2004). Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin. Circulation Research, 95(11), 1046–1057. https://doi.org/10.1161/01.RES.0000149165.99974.12CrossRefPubMed

32.

Kaden, J. J., Bickelhaupt, S., Grobholz, R., Haase, K. K., Sarikoç, A., Kiliç, R., Brueckmann, M., Lang, S., Zahn, I., Vahl, C., Hagl, S., Dempfle, C. E., & Borggrefe, M. (2004). Receptor activator of nuclear factor-kappaB ligand and osteoprotegerin regulate aortic valve calcification. Journal of Molecular and Cellular Cardiology, 36(1), 57–66. https://doi.org/10.1016/j.yjmcc.2003.09.015CrossRefPubMed

33.

Bucay, N., Sarosi, I., Dunstan, C. R., Morony, S., Tarpley, J., Capparelli, C., Scully, S., Tan, H. L., Xu, W., Lacey, D. L., Boyle, W. J., & Simonet, W. S. (1998). osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes & Development, 12(9), 1260–1268. https://doi.org/10.1101/gad.12.9.1260CrossRef

34.

Bennett, B. J., Scatena, M., Kirk, E. A., Rattazzi, M., Varon, R. M., Averill, M., Schwartz, S. M., Giachelli, C. M., & Rosenfeld, M. E. (2006). Osteoprotegerin inactivation accelerates advanced atherosclerotic lesion progression and calcification in older ApoE−/− mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 26(9), 2117–2124. https://doi.org/10.1161/01.ATV.0000236428.91125.e6CrossRefPubMed

35.

Alehagen, U., Aaseth, J., Alexander, J., Johansson, P., & Larsson, A. (2020). Supplemental selenium and coenzyme Q10 reduce glycation along with cardiovascular mortality in an elderly population with low selenium status—A four-year, prospective, randomised, double-blind placebo-controlled trial. Journal of Trace Elements in Medicine and Biology, 61, 126541. https://doi.org/10.1016/j.jtemb.2020.126541CrossRefPubMed

36.

Alehagen, U., Alexander, J., Aaseth, J., & Larsson, A. (2019). Decrease in inflammatory biomarker concentration by intervention with selenium and coenzyme Q10: A subanalysis of osteopontin, osteoprotergerin, TNFr1, TNFr2 and TWEAK. Journal of Inflammation (London, England), 16, 5. https://doi.org/10.1186/s12950-019-0210-6CrossRef

37.

Asanuma, Y., Chung, C. P., Oeser, A., Solus, J. F., Avalos, I., Gebretsadik, T., Shintani, A., Raggi, P., Sokka, T., Pincus, T., & Stein, C. M. (2007). Serum osteoprotegerin is increased and independently associated with coronary-artery atherosclerosis in patients with rheumatoid arthritis. Atherosclerosis, 195(2), e135–e141. https://doi.org/10.1016/j.atherosclerosis.2007.04.049CrossRefPubMedPubMedCentral

38.

Shao, J. S., Cheng, S. L., Sadhu, J., & Towler, D. A. (2010). Inflammation and the osteogenic regulation of vascular calcification: A review and perspective. Hypertension, 55(3), 579–592. https://doi.org/10.1161/HYPERTENSIONAHA.109.134205CrossRefPubMed

39.

Schoppet, M., Schaefer, J. R., & Hofbauer, L. C. (2003). Low serum levels of soluble RANK ligand are associated with the presence of coronary artery disease in men. Circulation, 107(11), e76. https://doi.org/10.1161/01.cir.0000060815.25798.02CrossRefPubMed

40.

Semb, A. G., Ueland, T., Aukrust, P., Wareham, N. J., Luben, R., Gullestad, L., Kastelein, J. J., Khaw, K. T., & Boekholdt, S. M. (2009). Osteoprotegerin and soluble receptor activator of nuclear factor-kappaB ligand and risk for coronary events: A nested case-control approach in the prospective EPIC-Norfolk population study 1993–2003. Arteriosclerosis, Thrombosis, and Vascular Biology, 29(6), 975–980. https://doi.org/10.1161/ATVBAHA.109.184101CrossRefPubMed

41.

Mohammadpour, A. H., Shamsara, J., Nazemi, S., Ghadirzadeh, S., Shahsavand, S., & Ramezani, M. (2012). Evaluation of RANKL/OPG serum concentration ratio as a new biomarker for coronary artery calcification: A pilot study. Thrombosis, 2012, 306263. https://doi.org/10.1155/2012/306263CrossRefPubMedPubMedCentral

42.

Bernardes, M., Vieira, T. S., Martins, M. J., Lucas, R., Costa, L., Pereira, J. G., Ventura, F., & Martins, E. (2017). Myocardial perfusion in rheumatoid arthritis patients: Associations with traditional risk factors and novel biomarkers. BioMed Research International, 2017, 6509754. https://doi.org/10.1155/2017/6509754CrossRefPubMedPubMedCentral

43.

Ellulu, M. S., Patimah, I., Khaza’ai, H., Rahmat, A., & Abed, Y. (2017). Obesity and inflammation: The linking mechanism and the complications. Archives of Medical Science, 13(4), 851–863. https://doi.org/10.5114/aoms.2016.58928CrossRefPubMed

44.

Elisia, I., Lam, V., Cho, B., Hay, M., Li, M. Y., Yeung, M., Bu, L., Jia, W., Norton, N., Lam, S., & Krystal, G. (2020). The effect of smoking on chronic inflammation, immune function and blood cell composition. Scientific Reports, 10(1), 19480. https://doi.org/10.1038/s41598-020-76556-7CrossRefPubMedPubMedCentral

45.

Duntas, L. H., & Hubalewska-Dydejczyk, A. (2015). Selenium and inflammation-potential use and future perspectives. US Endocrinology, 11(2), 97–102. https://doi.org/10.17925/use.2015.11.02.97CrossRef

46.

Costa, L. C., Fonseca, M., Pinheiro, A., Aguiar, T., Machado, A. N., Quinelato, V., Bonato, L. L., Aguiar, D. P., Vieira, T., Almeida, F., Lobo, J. C., Jordão, M., Lomardo, P. G., Granjeiro, J. M., & Casado, P. L. (2018). Chronic periodontitis and RANKL/OPG ratio in peri-implant mucosae inflammation. Brazilian Dental Journal, 29(1), 14–22. https://doi.org/10.1590/0103-6440201801241CrossRefPubMed

47.

Straface, G., Biscetti, F., Pitocco, D., Bertoletti, G., Misuraca, M., Vincenzoni, C., Snider, F., Arena, V., Stigliano, E., Angelini, F., Iuliano, L., Boccia, S., de Waure, C., Giacchi, F., Ghirlanda, G., & Flex, A. (2011). Assessment of the genetic effects of polymorphisms in the osteoprotegerin gene, TNFRSF11B, on serum osteoprotegerin levels and carotid plaque vulnerability. Stroke, 42(11), 3022–3028. https://doi.org/10.1161/STROKEAHA.111.619288CrossRefPubMed

48.

Duan, P., Wang, Z. M., Liu, J., Wang, L. N., Yang, Z., & Tu, P. (2015). Association of gene polymorphisms in RANKL/RANK/OPG system with hypertension and blood pressure in Chinese women. Journal of Human Hypertension, 29(12), 749–753. https://doi.org/10.1038/jhh.2015.13CrossRefPubMed

49.

Yang, T., Lee, S. Y., Park, K. C., Park, S. H., Chung, J., & Lee, S. (2022). The effects of selenium on bone health: From element to therapeutics. Molecules, 27(2), 392. https://doi.org/10.3390/molecules27020392CrossRefPubMedPubMedCentral

Title: Association Between Serum Selenium Concentration and OPG/RANKL/RANK Axis in Patients with Arterial Hypertension
Authors: Karolina Czerwińska
Małgorzata Poręba
Adam Prokopowicz
Lidia Januszewska
Aleksandra Jaremków
Iwona Markiewicz-Górka
Helena Martynowicz
Grzegorz Mazur
Rafał Poręba
Krystyna Pawlas
Paweł Gać
Publication date: 12-04-2022
Publisher: Springer US
Keywords: Hypertension
Arterial Hypertension
Arterial Hypertension
Published in: Cardiovascular Toxicology / Issue 7/2022
Print ISSN: 1530-7905
Electronic ISSN: 1559-0259
DOI: https://doi.org/10.1007/s12012-022-09741-x

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Association Between Serum Selenium Concentration and OPG/RANKL/RANK Axis in Patients with Arterial Hypertension

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 7/2022

Evaluating the Role of lncRNAs in the Incidence of Cardiovascular Diseases in Androgenetic Alopecia Patients

Investigating Radioprotective Effect of Hesperidin/Diosmin Compound Against 99mTc-MIBI-Induced Cardiotoxicity: Animal Study

Protective Effect of Curcumin, Chrysin and Thymoquinone Injection on Trastuzumab-Induced Cardiotoxicity via Mitochondrial Protection

Mesenchymal Stem Cell-Derived Exosome-Loaded microRNA-129-5p Inhibits TRAF3 Expression to Alleviate Apoptosis and Oxidative Stress in Heart Failure

The Cardiotoxic Effect of Roundup® is not Induced by Glyphosate: A Non-specific Blockade of Human CaV1.2 Channels

microRNA miR-133a as a Biomarker for Doxorubicin-Induced Cardiotoxicity in Women with Breast Cancer: A Signaling Pathway Investigation

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page